Drug Patents owned by Leo Pharma As

1. Drug name - ENSTILAR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9119781 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid Jun, 2031

(8 years from now)

US10688108 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid Jun, 2031

(8 years from now)

US10660908 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid Jun, 2031

(8 years from now)

US9566286 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid Jun, 2031

(8 years from now)

US10716799 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid Jun, 2031

(8 years from now)

US10682364 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid Jun, 2031

(8 years from now)

US10617698 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid Jun, 2031

(8 years from now)

US10130640 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid Jun, 2031

(8 years from now)

US10130640

(Pediatric)

LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid Dec, 2031

(9 years from now)

US9119781

(Pediatric)

LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid Dec, 2031

(9 years from now)

Drugs and Companies using BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE ingredient

Treatment: Plaque psoriasis; topical treatment of plaque psoriasis in patients 12 years and older; Topical treatment of plaque psoriasis in patients 12 years and older

Dosage: AEROSOL, FOAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.064%;0.005% AEROSOL, FOAM;TOPICAL Prescription

2. Drug name - FINACEA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8900554 LEO PHARMA AS Foamable composition and uses thereof Oct, 2023

(1 year, 24 days from now)

US10322085 LEO PHARMA AS Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof Oct, 2023

(1 year, 24 days from now)

US8722021 LEO PHARMA AS Foamable carriers Oct, 2023

(1 year, 24 days from now)

US8435498 LEO PHARMA AS Penetrating pharmaceutical foam Mar, 2024

(1 year, 5 months from now)

US7700076 LEO PHARMA AS Penetrating pharmaceutical foam Sep, 2027

(4 years from now)

US10117812 LEO PHARMA AS Foamable composition combining a polar solvent and a hydrophobic carrier Oct, 2027

(5 years from now)

US9265725 LEO PHARMA AS Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof Dec, 2027

(5 years from now)

US9211259 LEO PHARMA AS Antibiotic kit and composition and uses thereof Feb, 2029

(6 years from now)

Drugs and Companies using AZELAIC ACID ingredient

Treatment: Topical treatment of inflammatory papules and pustules of mild to moderate rosacea

Dosage: AEROSOL, FOAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
15% AEROSOL, FOAM;TOPICAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.